Gastric cancer (GC), the second most common malignancy globally and with 3% to 10% of all cancer-related mortality, has long been a life-threatening disease sophisticated by limitless factors interfering with its treatment (
1-
3). Despite the valuable efforts for improving the treatment strategies for GC cancer, still, a considerable proportion of patients lose their lives mainly due to the induction of drug resistance (
4,
5). Even the addition of trastuzumab to the first-line treatment of cancer, either as a single agent or in combination with paclitaxel, was not successful enough to prolong the overall survival of the patients (
6). However, the recent advances in the novel strategies such as gene therapy and its success in the treatment of a wide range of inherited and acquired human diseases have shed a ray of hope for the treatment of cancer patients, especially GC patients (
7).
Introducing genes by plasmids into the genome of tumoral cells and generating appropriate quantities of the gene product to induce compulsory cell death mediated by overexpression of a specific tumor-suppressor gene is an appealing application of gene therapy in the field of cancer therapy (
8). Among a wide variety of genes that could be fused with the genome, death-associated protein kinase 3 (DAPK3) is one of the most investigated ones (
9,
10). Through interplaying with a variety of signaling pathways, DAPK3, the third member of the DAPK enzymes family, could regulate a vast array of cellular functions, including caspase-dependent apoptotic cell death, autophagy, cell adhesion, as well as cell migration (
11). The biological role of DAPK3 in cells has been gradually investigated in recent years (
12). Death-associated protein kinase 3 is pro-apoptotic and carries out this function eithervia type I (caspase-dependent) apoptotic or type II (caspase-independent) autophagic cell deaths (
12). Death-associated protein kinase 3 also plays an important role in mediating inflammatory signals such as L13a (ribosome protein), ERK, and inhibiting interferon-activated translation (IFN) (
12). The contributory role of DAPK3 has been examined in different cancer cell types; however, in many cases, there are conflicting results. Although numerous investigations are emphasizing the anti-tumor activity of DAPK3, other studies declare that the overexpression of DAPK3 in cancer cells is in favor of tumor cell survival (
13). Despite several studies, the exact molecular activity of DAPK3 and the signals that regulate DAPK3 activity in cancer cells have not been fully elucidated and more research needs to be conducted (
12). Nevertheless, the data regarding the effect of this protein on cancer cells through the apoptotic and autophagy pathways are preliminary (
12). Therefore, in the present study, we investigated the effect of DAPK3 overexpression, using the non-viral PEGFPN1 vector on a well-known human gastric adenocarcinoma cell line and examined its overexpression impacts on gastric carcinoma.